H-Phe-Pro-Arg-OH

CAS No. 37553-80-3

H-Phe-Pro-Arg-OH( ——— )

Catalog No. M40458 CAS No. 37553-80-3

H-Phe-Pro-Arg-OH

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    H-Phe-Pro-Arg-OH
  • Note
    Research use only, not for human use.
  • Brief Description
    H-Phe-Pro-Arg-OH
  • Description
    H-Phe-Pro-Arg-OH
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    37553-80-3
  • Formula Weight
    ———
  • Molecular Formula
    ———
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • O-Acetyl-L-serine hy...

    O-Acetylserine (OASS) is an acylated amino acid derivative. It is an intermediate in the biosynthesis of the common amino acid cysteine in bacteria and plants. Its presence in humans arises from either microbial metabolism in the gut or through consumption of foods containing OASS.

  • PKR-IN-C16

    PKR-IN-C16 is a specific protein kinase (PKR) inhibitor.?PKR-IN-C16 is able to inhibit the autophosphorylation of PKR and unlock the translation blockade induced by PKR in primary neuronal cultures.PKR-IN-C16 binds the ATP-binding site of PKR and blocks autophosphorylation with an IC50 value of 186-210 nM.?

  • Remimazolam

    Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?